Condition: Intracranial Meningioma · Recurrent Meningioma · NF2 Gene Mutation · Sponsor: Alliance for Clinical Trials in Oncology
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Priscilla Brastianos, MD · 617-643-1939
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | Recruiting |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | Suspended |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Recruiting |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | Suspended |
| Katmai Oncology Group | Anchorage, Alaska, United States | Recruiting |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Recruiting |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | Recruiting |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | Recruiting |
+ 768 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02523014